Chimeric antigen receptor T-cell (CAR-T) therapies are standard of care for the treatment of several hematologic malignancies. Although patients receiving CAR-T therapies are frequently hospitalized ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

UAE's Burjeel Holdings has joined forces with US-based non-profit Caring Cross to locally manufacture CAR-T (Chimeric Antigen ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Chimeric antigen receptor (CAR-T) cell therapy is a rapidly growing frontier in cancer research, with Australian biotech ...

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...